List of Tables:
Table 1. Snapshot of Europe Biosimilars Market in Balanced Perspective, 2019-2030 17
Table 2. Growth Rate of World GDP, 2020-2022 23
Table 3. World Health Spending by Region, $ bn, 2013-2020 31
Table 4. Main Product Trends and Market Opportunities in Europe Biosimilars Market 35
Table 5. Europe Biosimilars Market by Product Type, 2019-2030, $ mn 43
Table 6. Europe Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, $ mn 46
Table 7. Europe Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, $ mn 51
Table 8. Europe Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, $ mn 55
Table 9. Europe Biosimilars Market by Indication, 2019-2030, $ mn 59
Table 10. Europe Biosimilars Market by Manufacturing, 2019-2030, $ mn 68
Table 11. Europe Biosimilars Market by End User, 2019-2030, $ mn 72
Table 12. Europe Biosimilars Market by Country, 2019-2030, $ mn 79
Table 13. Approved Biosimilars in Europe 80
Table 14. Germany Biosimilars Market by Product Type, 2019-2030, $ mn 83
Table 15. Germany Biosimilars Market by Indication, 2019-2030, $ mn 83
Table 16. Germany Biosimilars Market by End User, 2019-2030, $ mn 83
Table 17. U.K. Biosimilars Market by Product Type, 2019-2030, $ mn 87
Table 18. U.K. Biosimilars Market by Indication, 2019-2030, $ mn 87
Table 19. U.K. Biosimilars Market by End User, 2019-2030, $ mn 87
Table 20. France Biosimilars Market by Product Type, 2019-2030, $ mn 89
Table 21. France Biosimilars Market by Indication, 2019-2030, $ mn 89
Table 22. France Biosimilars Market by End User, 2019-2030, $ mn 89
Table 23. Spain Biosimilars Market by Product Type, 2019-2030, $ mn 91
Table 24. Spain Biosimilars Market by Indication, 2019-2030, $ mn 91
Table 25. Spain Biosimilars Market by End User, 2019-2030, $ mn 91
Table 26. Italy Biosimilars Market by Product Type, 2019-2030, $ mn 93
Table 27. Italy Biosimilars Market by Indication, 2019-2030, $ mn 93
Table 28. Italy Biosimilars Market by End User, 2019-2030, $ mn 93
Table 29. Russia Biosimilars Market by Product Type, 2019-2030, $ mn 95
Table 30. Russia Biosimilars Market by Indication, 2019-2030, $ mn 95
Table 31. Russia Biosimilars Market by End User, 2019-2030, $ mn 95
Table 32. Biosimilars Market in Rest of Europe by Country, 2019-2030, $ mn 97
Table 33. Breakdown of World Market by Key Vendor, 2020, % 100
Table 34. AMEGA Biotech S.A.: Company Snapshot 103
Table 35. AMEGA Biotech S.A.: Business Segmentation 103
Table 36. AMEGA Biotech S.A.: Product Portfolio 104
Table 37. AMEGA Biotech S.A.: Revenue, 2018-2020, $ mn 104
LIST OF FIGURE
List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. Europe Biosimilars Market, 2019-2030, $ mn 19
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 20
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21
Figure 8. Impact of COVID-19 on Business 25
Figure 9. Primary Drivers and Impact Factors of Europe Biosimilars Market 27
Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 12. Primary Restraints and Impact Factors of Europe Biosimilars Market 32
Figure 13. Investment Opportunity Analysis 36
Figure 14. Porters Fiver Forces Analysis of Europe Biosimilars Market 39
Figure 15. Breakdown of Europe Biosimilars Market by Product Type, 2019-2030, % of Revenue 44
Figure 16. Europe Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%) 44
Figure 17. Europe Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn 45
Figure 18. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn 47
Figure 19. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn 48
Figure 20. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn 49
Figure 21. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn 50
Figure 22. Europe Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn 51
Figure 23. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn 52
Figure 24. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn 53
Figure 25. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn 54
Figure 26. Europe Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn 55
Figure 27. Europe Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn 56
Figure 28. Europe Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn 57
Figure 29. Europe Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn 58
Figure 30. Breakdown of Europe Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 60
Figure 31. Europe Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%) 60
Figure 32. Europe Biosimilars Market by Indication: Cancer, 2019-2030, $ mn 61
Figure 33. Europe Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn 62
Figure 34. Europe Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn 63
Figure 35. Europe Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn 64
Figure 36. Europe Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn 65
Figure 37. Europe Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn 66
Figure 38. Europe Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn 67
Figure 39. Breakdown of Europe Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 69
Figure 40. Europe Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%) 69
Figure 41. Europe Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn 70
Figure 42. Europe Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn 71
Figure 43. Breakdown of Europe Biosimilars Market by End User, 2019-2030, % of Revenue 73
Figure 44. Europe Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%) 73
Figure 45. Europe Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn 74
Figure 46. Europe Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn 75
Figure 47. Europe Biosimilars Market by End User: Other End Users, 2019-2030, $ mn 76
Figure 48. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue 78
Figure 49. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 79
Figure 50. Biosimilars Market in Germany, 2019-2030, $ mn 82
Figure 51. Biosimilars Market in U.K., 2019-2030, $ mn 85
Figure 52. Biosimilars Market in France, 2019-2030, $ mn 88
Figure 53. Biosimilars Market in Spain, 2019-2030, $ mn 90
Figure 54. Biosimilars Market in Italy, 2019-2030, $ mn 92
Figure 55. Biosimilars Market in Russia, 2019-2030, $ mn 94
Figure 56. Biosimilars Market in Rest of Europe, 2019-2030, $ mn 96
Figure 57. Growth Stage of Europe Biosimilars Industry over the Forecast Period 98
